BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

The vaccine maker is expanding beyond its COVID-focused offerings.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

Investing.com -- Moderna (NASDAQ:MRNA) stock rose 10% on Thursday, extending its winning streak to a fourth consecutive session and reaching its highest intraday level since November 2024.

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna Inc. (MRNA) stock reached a significant milestone, hitting a 52-week high of $45.44. This achievement marks a notable point in the company’s performance over the past year. According to ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...